Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Michael W Simon MD PSC

Neither a doctor nor a teaching hospital

Research payments

$759,931

276 payments

Through program year 2025, Michael W Simon MD PSC is reported as receiving $759,931 in research payments, across 276 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $124,090 41
2024 Research $86,074 42
2023 Research $118,024 40
2022 Research $52,618 26
2021 Research $171,074 66
2020 Research $122,417 38
2019 Research $85,633 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $400,564 139 payments
  2. Novavax Inc $126,700 50 payments
  3. Moderna TX, Inc. $89,287 13 payments
  4. AbbVie, Inc. $83,750 38 payments
  5. GlaxoSmithKline, LLC. $50,670 30 payments
  6. Allergan Inc. $8,960 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $173,683 39 payments
  2. A Phase 2 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine Given With Or Separately From 13Valent Pneumococcal Conjugate Vaccine in Healthy Infants $123,600 41 payments
  3. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults $87,494 12 payments
  4. Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years $61,113 23 payments
  5. Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) $44,116 14 payments
  6. A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in Children 6 Months to < 12 Years of Age $42,171 11 payments
  7. A Phase 3 Singlearm Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through 17 Years of Age $39,584 11 payments
  8. A Phase 2B, Randomized, Observer-Blinded Trial to Describe the Safety, $38,606 22 payments
  9. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $35,847 19 payments
  10. A Phase 3 Randomized Activecontrolled Observerblinded Trial to Assess the Safety Tolerability and Immunogenicity of Menabcwy in Healthy Participants 10 to 26 Years of Age $23,700 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record